The developer of China’s first approved Covid-19 antibody cocktail said lab tests had found the treatment “holds up well” against the new Omicron variant, though one of the antibodies had a “substantial drop in activity”.Brii Biosciences on Sunday also again said its therapy “retains activity” against major coronavirus strains including the highly transmissible Delta variant and its sub-lineage Delta Plus.China’s medical products regulator approved its use last Wednesday. The company said the…
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Covid-19 News Click Here